CannabisNewsWire Editorial Coverage: The U.S. Farm Bill that recently passed into law is a game-changer for the CBD space. While it is unknown when nationwide cannabis legalization may occur, incredible opportunities exist right now for CBD-focused companies that can deliver products to the marketplace.
- Demand is growing for organic CBD products in markets where such products are legal.
- Youngevity has made a series of strategic acquisitions to help establish the company’s position
- Companies ready to deliver CBD products to market at scale are in ideal position to capitalize on growing demand.
Passage of the latest U.S. Farm Bill marked a watershed moment for CBD producers in the United States. Not only does the new body of law allow these producers to commercialize existing CBD products, the door is now open for a new generation of research into what CBD can do for consumers. Youngevity International Inc. (NASDAQ: YGYI) (YGYI Profile) is a leading producer of consumer-focused CBD products that is expanding its reach into other areas of the CBD supply chain. It joins companies such as CV Sciences Inc. (OTCQB: CVSI), Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF), GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC: GWPRF), and Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA), which are all working to commercialize CBD products in both the consumer and pharmaceutical sectors.
CBD Offers New Opportunities for Bold Thinkers
The market for CBD products is exploding and likely will continue to grow as these products become more available. Because CBD can be made in a laboratory, an increasing amount of synthetically produced CBD has been entering the market. However, many CBD proponents contend that organic CBD (CBD extracted from hemp plants) is superior to synthetic CBD.
Youngevity International Inc. (NASDAQ: YGYI) produces a range of consumer-focused CBD products, but the company is growing its reach via strategic acquisitions. Sourcing organic CBD has been an issue for many manufacturers, which may be why Youngevity recently acquired Khrysos Global — a CBD producer based in Florida.
Following the announcement of this acquisition to the public, YGYI president and CFO Dave Briskie commented, “We set out a plan to create a vertical opportunity in the hemp space. This is a significant step as it relates to the production, cultivation, and extraction of hemp, CBD oil, as well as other CBs (cannabinoids). . . . We proudly welcome Dwayne Dundore, as the President of newly formed Khyrsos (sic) Industries along with his entire and very capable team at Khrysos and INX Labs.”
Dundore was equally enthusiastic about the announcement, saying, “I am really excited to be a YGYI shareholder and part of the Youngevity Family. I look forward to making a meaningful contribution to both the top and bottom line of the company and feel strongly that our capabilities and plans for expansion should create additional value for myself and all shareholders.”
CBD Ready to Take the Market by Storm
Unlike THC, which is a highly psychoactive alkaloid found in cannabis, CBD has a calming effect in most people. In addition, CBD can be legally sold without a prescription and is being integrated into many consumer products.
CBD companies that can create good connections with their client bases should be able to grow into this burgeoning market. Recognizing this, Youngevity has made a series of strategic acquisitions that could help establish the company’s position as a leader in 21st-century cannabis development. The company’s takeover of Khrysos Global netted it a solid supply of organic CBD, as Khrysos has both cannabis cultivation property and facilities to refine CBD oil.
With that backdrop, Youngevity recently launched HempFX to sell its products directly to consumers. For the moment, the company is offering hemp oils. Its product line may increase as additional research and development brings more ideas to market.
A Coffee Door Opener
Youngevity is also ready to bring a CBD-infused coffee to market. Its recent acquisition of Khrysos Global brought CBD-testing laboratories to the company, looking to leave Youngevity in a position to take full advantage of the new U.S. CBD laws. One of the biggest hurdles for manufacturers of CBD products is making sure the products contain a repeatable dose of CBD. Through careful testing, Youngevity has overcome this obstacle in its coffee, which reliably delivers 10mg of CBD in every cup.
The new coffee will be made by Youngevity’s wholly owned subsidiary CLR Roasters. According to the company, the new product will be sold in four flavors and will be available to consumers later this year.
CLR Roasters president Ernesto Aguila commented, “We are extremely pleased with the taste of the product, and the samples that we have provided to a host of retailers have led to strong reviews as well. It is very exciting to bring a new product to market that has so much interest within the coffee beverage category. I have not seen a door opener like this since Javalution Coffee Company created the first fortified coffees.”
Market Viability Looks Strong
CBD has essentially been illegal since modern medicine began. Now that it is legal to produce and distribute CBD in the United States, early movers in the space are setting themselves up for potentially massive profits. Numerous companies are focusing on developing better CBD-infused products, creating new forms of consumer-focused CBD consumables and getting those products to consumers as quickly and easily as possible.
CV Sciences Inc. (OTCQB: CVSI) is working to commercialize CBD products for both consumers and the medical community. Its pharmaceutical division is looking to create a CBD-based medicine that can be approved by the U.S. Food and Drug Administration. Now that CBD is 100 percent legal at a federal level in the United States, the company should be able to make progress on this project. Its consumer division is developing a range of products that can be sold to health food stores or directly to its customers. As CBD use has become more widespread, there is a growing amount of feedback from users to support its continued development.
Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) has built a CBD-focused business with operations in the United States, the United Kingdom, and other countries. Kevin Swadish, the company’s chief revenue officer, commented, “The legalities of hemp-based CBD are becoming more favorable, and consumer awareness of CBD is rapidly rising. As a result, we believe the greatest growth opportunities in the industry, and for Isodiol, lie in the consumer packaged goods marketplace.” The company has built up an operation with more than 200 employees and consultants globally, which demonstrates the interest CBD has generated in recent years.
GW Pharmaceuticals plc (NASDAQ: GWPH) (OTC: GWPRF) developed the first marijuana-derived pharmaceutical to be approved by the FDA. Epidiolex, which contains CBD, was designed to treat Dravet syndrome and was the first drug ever approved to treat this rare form of epilepsy in the U.S. Sales of the drug began last November, and according to recent financial results posted by the company, Epidiolex has garnered substantial interest. Epidiolex sales totaled around $4.7 million in the last quarter, with more than 4,500 new patient enrollment forms during the first two months the drug was available. The positive results from Epidiolex sales were well received, and investors bid the company’s shares higher after they were announced.
Getting CBD products into the hands of consumers is also a focus for savvy companies looking to the future. Curaleaf Holdings Inc. (OTCQX: CURLF) (CSE: CURA) recently announced a distribution deal with CVS Health Corp. Under the new deal, the retail pharmacy and healthcare company will begin selling products infused with the trendy, nonintoxicating hemp component at more than 800 of its stores nationwide. CVS confirmed that it has started selling CBD creams, sprays and lotions in eight states, including California, Illinois, Colorado and Alabama. The products will be sold in store aisles. “We’ve been having dialogue with national retailers for many months now,” said Curaleaf chief executive officer Joseph Lusardi. “We’ve got a number of potentially exciting partnerships in the pipeline.”
Growing hemp and refining it into CBD could become profitable for companies that can do it efficiently, especially if public demand grows faster than production capacity. Youngevity may be picking up on this emerging market dynamic and securing its supplies of organic CBD while the industry is still in its infancy.
For more information on Youngevity, visit Youngevity International, Inc. (NASDAQ: YGYI)
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.